Börse von finanzen.net | Aktien-Nachrichten | Marktberichte

DAX	6.050	-3,4%	Dow	12.119	-2,2%	Euro	1,2432	0,6%
ESt50	2.069	-2,4%	Nas	2.748	-2,8%	Öl	98,82	-2,8%
TDax	730,9	-2,7%	Nikkei	8.440	-1,2%	Gold	1.626	4,2%

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Depot
Times + Sales	Chart-Analyse	Analysen	Dividende/HV	Profil	Optionsscheine	Watchlist
Börsenplätze	Chartvergleich	Kursziele		Insidertrades	Knock-outs	myHome
Orderbuch	Realtime Stuttgart	RSS Feed		im Forum	Fonds	Senden
Historisch	Realtime Push	myNews neu		IR-Daten	Anleihen	handeln

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

myNews neu

handeln

31.05.12	Karo Bio Implements Planned Efficiency Measures
22.05.12	Karo Bio: Karo Bio’s Annual Report Now Available
11.05.12	Notice of Annual General Meeting of Karo Bio AB (Publ)
27.04.12	Extraordinary General Meeting in Karo Bio
27.04.12	Karo Bio: Interim Report January - March 2012
02.04.12	Collaboration with Zydus Cadila Expires – Karo Bio Continues to Develop Safer Glucocorticoids
23.03.12	Changed Date for the Annual General Meeting and Notice to Extraordinary General Meeting of Karo Bio
21.02.12	Karo Bio Lays off 16 Employees
14.02.12	Karo Bio Terminates the Eprotirome Program
13.02.12	Karo Bio: Information regarding trading suspension

08.02.12	Karo Bio: Interim Report January - December 2011
01.11.11	Karo Bio Issues Notice of Redundancy for 25 Employees
25.10.11	Karo Bio: Interim Report January–September 2011
25.10.11	Karo Bio Prepares Spin-off of Preclinical Development
24.10.11	Karo Bio: Per Bengtsson Appointed CEO
18.10.11	Karo Bio: Presentation of the Interim Report
04.10.11	Karo Bio: First Patient Included in Phase III Study
30.09.11	Changes in management of Karo Bio AB
19.09.11	Go-Ahead for Karo Bio Phase III Study
17.08.11	Changes in Management Of Karo Bio AB
13.07.11	Karo Bio: Interim Report January–June 2011
08.07.11	Karo Bio: Presentation of the Interim Report January- June 2011
24.05.11	KARO BIO AB Appoints Per Bengtsson as Acting President and CEO
04.05.11	Shareholder Proposal about Election of Board of Directors and Nominating Committee in Karo Bio AB (PUBL)
28.04.11	The Annual General Meeting of Karo Bio AB (Publ) Adjourned
27.04.11	Karo Bio: Interim Report January–March 2011
26.04.11	Karo Bio and Alkem Laboratories Ltd Collaborate to Develop Eprotirome
25.03.11	Karo Bio: Karo Bio’s Annual Report Now Available
25.03.11	Notice of Annual General Meeting of Shareholders of Karo Bio
21.03.11	Karo Bio and Zydus Cadila Extend Research Agreement
09.02.11	Karo Bio: Interim Report January – December 2010
31.01.11	Change in Number of Shares and Votes in Karo Bio (Publ)
22.12.10	Karo Bio: Karo Bio’s Rights Issue Fully Subscribed
25.11.10	Karo Bio Announces Prospectus for the Rights Issue
25.11.10	Resolutions Passed by the General Meeting of Karo Bio AB (Publ)
22.11.10	Karo Bio Announces Terms for the Rights Issue
26.10.10	Karo Bio: Interim Report January–September 2010
26.10.10	Notice of Extraordinary General Meeting of Karo Bio AB (publ)
26.10.10	Karo Bio Secures Financing of Approximately SEK 530 Million for Phase III Trials of Eprotirome
28.04.10	Karo Bio: Karo Bio’s CEO Buys Shares in the Company

Finanzen.net

Karo Bio AB (B) Aktie [WKN: 913089 / ISIN: SE0000571416]

Hinweis

Newssuche

ALLE Nachrichten zur Karo Bio AB (B)

Anzeige

ANZEIGE